Ovarian and oocyte targets for development of female contraceptives

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 11, 2015, Pages 1433-1446

  Gupta, Satish Kumar ^a   Malik, Ankita ^a   Arukha, Ananta Prasad ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

anti angiogenic agent; contraceptive vaccines; COX 2 inhibitor; estrogen receptor modulator; follicle stimulating hormone receptor; gonadotropin releasing hormone; human chorionic gonadotropin; PDE3 inhibitor; progesterone receptor modulator; steroid hormonebased contraceptives; zona pellucida

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; CARBOXY TERMINUS PEPTIDE; CHORIONIC GONADOTROPIN; CONTRACEPTIVE AGENT; CONTRACEPTIVE VACCINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA; ESTROGEN RECEPTOR; FOLLITROPIN RECEPTOR; FOLLITROPIN RECEPTOR BINDING INHIBITOR; GLYCOPROTEIN; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; MONOCLONAL ANTIBODY; PEPTIDE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR; RECOMBINANT PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID HORMONE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ENDOMETRIUM; FEMALE; FERTILIZATION; HORMONAL REGULATION; HUMAN; NONHUMAN; OOCYTE; OOCYTE MATURATION; OVARY; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; OVARY INFLAMMATION; OVULATION; PASSIVE IMMUNIZATION; REPRODUCTION; REVIEW; ZONA PELLUCIDA; ANIMAL; DRUG DESIGN; METABOLISM;

ANIMALS; CONTRACEPTIVE AGENTS, FEMALE; DRUG DESIGN; FEMALE; HUMANS; OOCYTES; OVARY; VACCINES, CONTRACEPTIVE;

EID: 84946729934     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1051305     Document Type: Review

References (91)

1. Current world population. Worldometers. Available from: http://www.worldometers.info/worldpopulation/[Last accessed 20 April 2015]
2. Groome NP, Illingworth PJ, O' Brien M, et al. Measurement of dimeric inhibin throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401-5
3. Dighe AS, Moy JM, Hayes FJ, Sluss PM. High-resolution reference ranges for estradiol, luteinizing hormone, and follicle-stimulating hormone in men and women using the AxSYM assay system. Clin Biochem 2005;38:175-9
4. Soyal SM, Amleh A, Dean J. FIGalpha, a germ cell-specific transcription factor required for ovarian follicle formation. Development 2000;127:4645-54
5. Lee WS, Yoon SJ, Yoon TK, et al. Effect of bone morphogenic protein-7 (BMP-7) on primordial follicular growth in the mouse ovary. Mol Reprod Dev 2004;69:159-63
6. Dong J, Albertini DF, Nishimori K, et al. Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature 1996;383:531-5
7. Visser JA, Themmen APN. Role of anti-Mullerian hormone and bone morphogenetic proteins in the regulation of FSH sensitivity. Mol Cell Endocrinol 2014;382:460-5
8. Emmen JM, Couse JF, Elmore SA, et al. In vitro growth and ovulation of follicles from ovaries of estrogen receptor (ER) {alpha} and ER{beta} null mice indicate a role for ER{beta} in follicular maturation. Endocrinology 2005;146:2817-26
9. Su YQ, Wu X, O'Brien MJ, et al. Synergistic roles of BMP15 and GDF9 in the development and function of the oocyte-cumulus cell complex in mice: genetic evidence for an oocytegranulosa cell regulatory loop. Dev Biol 2004;276:64-73
10. Rossmanith WG, Steffens D, Schramm G. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity. Contraception 1997;56:23-30
11. Bahamondes L, Bahamondes MV. New and emerging contraceptives: A state-ofthe-art review. Int J Women Health 2014;6:221-34
12. Bergendal A, Persson I, Odeberg J, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol 2014;124:600-9
13. Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. A double blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 microgrammes per day or levonorgestrel 30 microgrammes per day. Eur J Contracept Reprod Health Care 1998;3:169-78
14. von Hertzen H, Piaggio G, Van Look PF. Emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998;352:1939
15. Masciarelli S, Horner K, Liu C, et al. Cyclic nucleotide phosphodiesterase 3Adeficient mice as a model of female infertility. J Clin Invest 2004;114:196-205
16. Jensen JT, Zelinski MB, Stanley JE, et al. The phosphodiesterase 3 inhibitor ORG 9935 inhibits oocyte maturation in the naturally selected dominant follicle in rhesus macaques. Contraception 2008;77:303-7
17. Vanhoutte L, De Sutter P, Nogueira D, et al. Nuclear and cytoplasmic maturation of in vitro matured human oocytes after temporary nuclear arrest by phosphodiesterase 3-inhibitor. Hum Reprod 2007;22:1239-46
18. Li M, Yu Y, Yan J, et al. The Role of cilostazol, a phosphodiesterase 3 inhibitor, on oocyte maturation and subsequent pregnancy in mice. PLoS ONE 2012;7:e30649
19. Azevedo MF, Faucz FR, Bimpaki E, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 2014;35:195-233
20. Endo T, Kitajima Y, Nishikawa A, et al. Cyclic changes in expression of mRNA of vascular endothelial growth factor, its receptors Flt-1 and KDR/Flk-1, and Ets-1 in human corpora lutea. Fertil Steril 2001;76:762-8
21. Hazzard TM, Molskness TA, Chaffin CL, et al. Vascular endothelial growth factor (VEGF) and angiopoietin regulation by gonadotrophin and steroids in macaque granulosa cells during the peri-ovulatory interval. Mol Hum Reprod 1999;5:1115-21
22. Xu F, Hazzard TM, Evans A, et al. Intraovarian actions of anti-angiogenic agents disrupt periovulatory events during the menstrual cycle in monkeys. Contraception 2005;71:239-48
23. Hsueh AJ, Erickson GF. Extrapituitary action of gonadotropin releasing hormone: direct inhibition of steroidogenesis. Science 1979;204:854-5
24. Gudmundsson JA, Nillius SJ, Berqquist C. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months clinical trial. Fertil Steril 1986;45:617-23
25. Zarate A, Canales ES, Sthory I, et al. Anovulatory effect of a LHRH antagonist in women. Contraception 1981;24:315-20
26. Sheehan KL, Casper RF, Yen SS. Induction of luteolysis by luteinizing hormone-releasing factor (LRF) agonist: sensitivity, reproducibility and reversibility. Fertil Steril 1982;37:209-12
27. Fraser HM, Baird DT, McRae GI, et al. Suppression of luteal progesterone secretion in the stumptailed macaque by an antagonist analogue of luteinizing hormone-releasing hormone. J Endocrinol 1985;104:R1-4
28. Kumar TR, Wang Y, Lu N, et al. Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat Genet 1997;15:201-4
29. Dierrich A, Siaram MR, Monaco L, et al. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci USA 1998;95:13612-17
30. Aittomaki K, Lucena JL, Pakarinen P, et al. Mutation in the folliclestimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995;82:959-68
31. Wadia P, Khalkule S, Nandedkar T. Antifertility effect of an octapeptide, a fragment of FSH binding inhibitor, in the common marmoset (Callithrix jacchus). Contraception 2002;123:847-57
32. Van de Lagemaat R, van Koppen C, Krajnc-Frenken MA, et al. Contraception by induction of lutenized unruptured follicles with short-acting low molecular weight FSH receptor agonists in female animal models. Reproduction 2011;142:893-905
33. Dias JA, Campo B, Weaver BA, et al. Inhibition of follicle-stimulating hormone-induced preovulatory follicles in rats treated with non steroidal negative allosteric modulator of folliclestimulating hormone receptor. Biol Reprod 2014;90:19
34. Takahashi T, Morrow JD, Wang H, Dey SK. Cyclooxygenase-2 derived prostaglandin E(2) directs oocyte maturation by differentially influencing multiple signaling pathways. J Biol Chem 2006;281:37117-29
35. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-9
36. Jesam C, Salvatierra AM, Schwartz JL, Croxatto HB. Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception. Hum Reprod 2010;25:368-73
37. Gemzell-Danielsson K, Marions L. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. Hum Reprod Update 2004;10:341-8
38. Zhu HX, Zhang WW, Zhuang YL, Huang LL. Mifepristone as an antiimplantation contraceptive drug: roles in regulation of uterine natural killer cells during implantation phase. Am J Reprod Immunol 2009;61:68-74
39. Zhou F, Liang Y, Qian ZD, et al. Low-dose mifepristone increases uterine expression of aquaporin 1/aquaporin 2 at the time of implantation. Contraception 2013;87:844-9
40. Lakha F, Ho PC, Van der Spuy ZM, et al. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007;22:2428-36
41. Brache V, Cochon L, Deniaud M, Croxatto HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 2013;88:611-18
42. Stratton P, Levens ED, Hartog B, et al. Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. Fertil Steril 2010;93:2035-41
43. Keenan JA. Ulipristal acetate: contraceptive or contragestive? Ann Pharmacother 2011;45:813-15
44. Jensen JT. Vaginal ring delivery of selective progesterone receptor modulators for contraception. Contraception 2013;87:314-18
45. Makker A, Tandon I, Goel MM, et al. Effect of ormeloxifene, a selective estrogen receptor modulator, on biomarkers of endometrial receptivity and pinopode development and its relation to fertility and infertility in Indian subjects. Fertil Steril 2009;91:2298-307
46. Gupta SK, Singh O, Talwar GP. Characteristics and bioefficacy of monoclonal antigonadotropin releasing hormone antibody. Am J Reprod Immunol Microbiol 1985;7:104-8
47. Talwar GP, Gupta SK, Singh V, et al. Bioeffective monoclonal antibody against the decapeptide gonadotropin-releasing hormone: reacting determinant and action on ovulation and estrus suppression. Proc Natl Acad Sci USA 1985;82:1228-31
48. Das C, Gupta SK, Talwar GP. Pregnancy interfering action of LHRH and anti-LHRH. J Steroid Biochem 1985;23:803-6
49. Takahashi M, Ford JJ, Yoshinaga K, Greep RO. Active immunization of female rats with luteinizing hormone releasing hormone (LHRH). Biol Reprod 1978;18:754-61
50. Hodges JK, Hearn JP. Effect of immunisation against luteinizing hormone releasing hormone on reproduction of the marmoset monkeys, Callithrix jacchus. Nature 1977;265:746-8
51. Hsu CT, Ting CY, Ting CJ, et al. Vaccination against gonadotropinreleasing hormone (GnRH) using toxin receptor-binding domain-conjugated GnRH repeats. Cancer Res 2000;60:3701-5
52. Lussow AR, Barrios C, van Embden J, et al. Mycobacterium heat-shock proteins as carrier molecules. Eur J Immunol 1991;21:2297-302
53. Jinshu X, Jingjing L, Duan P, et al. A synthetic gonadotropin-releasing hormone (GnRH) vaccine for control of fertility and hormone dependent diseases without any adjuvant. Vaccine 2005;23:4834-43
54. Miller LA, Gionfriddo JP, Fagerstone KA, et al. The single-shot GnRH immunocontraceptive vaccine (GonaCon) in white-tailed deer: comparison of several GnRH preparations. Am J Reprod Immunol 2008;60:214-23
55. Simms MS, Scholfreld DP, Jacobs E, et al. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br J Cancer 2000;83:443-6
56. Parkinson RJ, Simms MS, Broome P, et al. A vaccination strategy for the longterm suppression of androgens in advanced prostate cancer. Eur Urol 2004;45:171-5
57. Gupta SK, Bhandari B, Shrestha A, et al. Mammalian zona pellucida glycoproteins: structure and function during fertilization. Cell Tissue Res 2012;349:665-78
58. Skinner SM, Mills T, Kirchik HJ, Dunbar BS. Immunization with zona pellucida proteins results in abnormal ovarian follicular differentiation and inhibition of gonadotropin-induced steroid secretion. Endocrinology 1984;115:2418-32
59. Mahi-Brown CA, Yanagimachi R, Hoffman JC, Huang TT Jr. Fertility control in the bitch by active immunization with porcine zonae pellucidae: use of different adjuvants and patterns of estradiol and progesterone levels in estrous cycles. Biol Reprod 1985;32:761-72
60. Sacco AG, Pierce DL, Subramanian MG, et al. Ovaries remain functional in squirrel monkeys (Saimiri sciureus) immunized with the porcine zona pellucida 55,000 macromolecule. Biol Reprod 1987;36:481-90
61. Bagavant H, Thillai-Koothan P, Sharma MG, et al. Antifertility effects of porcine zona pellucida-3 immunization using permissible adjuvants in female bonnet monkeys (Macaca radiata): reversibility, effect on follicular development and hormonal profiles. J Reprod Fertil 1994;102:17-25
62. Upadhyay SN, Thillai-Koothan P, Bamezai A, et al. Role of adjuvants in inhibitory influence of immunization with porcine zona pellucida antigen (ZP-3) on ovarian folliculogenesis in bonnet monkeys: A morphological study. Biol Reprod 1989;41:665-73
63. Govind CK, Srivastava N, Gupta SK. Evaluation of the immunocontraceptive potential of Escherichia coli-expressed recombinant non-human primate zona pellucida glycoproteins in homologous animal model. Vaccine 2002;21:78-88
64. Paterson M, Wilson MR, Morris KD, et al. Evaluation of the contraceptive potential of recombinant human ZP3 and human ZP3 peptides in a primate model: their safety and efficacy. Am J Reprod Immunol 1998;40:198-209
65. Govind CK, Gupta SK. Failure of female baboons (Papio anubis) to conceive following immunization with recombinant non-human primate zona pellucida glycoprotein-B expressed in Escherichia coli. Vaccine 2000;18:2970-8
66. Martinez ML, Harris JD. Effectiveness of zona pellucida protein ZPB as an immunocontraceptive antigen. J Reprod Fertil 2000;120:19-32
67. Gupta SK, Srinivasan VA, Suman P, et al. Contraceptive vaccine based on the zona pellucida glycoproteins for dogs and other wildlife population management. Am J Reprod Immunol 2011;66:51-62
68. Rhim SH, Millar SE, Robey F, et al. Autoimmune disease of the ovary induced by a ZP3 peptide from the mouse zona pellucida. J Clin Invest 1992;89:28-35
69. Lou AM, Garza KM, Hunt D, Tung KS. Antigen mimicry in autoimmune disease sharing of amino acid residues critical for pathogenic T cell activation. J Clin Invest 1993;92:2117-23
70. Lou Y, Ang J, Thai H, et al. A zona pellucida 3 peptide vaccine induces antibodies and reversible infertility without ovarian pathology. J Immunol 1995;155:2715-20
71. Hinsch E, Hägele W, Bohle RM, et al. Evaluation of ZP2 domain of functional importance with antisera against synthetic ZP2 peptides. J Reprod Fertil 1998;114:245-51
72. Hasegawa A, Hamada Y, Shigeta M, Koyama K. Contraceptive potential of synthetic peptides of zona pellucida protein (ZPA). J Reprod Immunol 2002;53:91-8
73. Sivapurapu N, Hasegawa A, Gahlay GK, et al. Efficacy of antibodies against a chimeric synthetic peptide encompassing epitopes of bonnet monkey (Macaca radiata) zona pellucida-1 and zona pellucida-3 glycoproteins to inhibit in vitro human sperm-egg binding. Mol Reprod Dev 2005;70:247-54
74. Hardy CM, ten Have JF, Mobbs KJ, Hinds LA. Assessment of the immunocontraceptive effect of a zona pellucida 3 peptide antigen in wild mice. Reprod Fertil Dev 2002;14:151-5
75. Sun W, Lou YH, Dean J, Tung KS. A contraceptive peptide vaccine targeting sulfated glycoprotein ZP-2 of the mouse zona pellucida. Biol Reprod 1999;60:900-7
76. Miller LA, Killian GJ. In search of the active PZP epitope in white-tailed deer immunocontraception. Vaccine 2002;20:2735-42
77. Kaul R, Sivapurapu N, Afzalpurkar A, et al. Immunocontraceptive potential of recombinant bonnet monkey (Macaca radiata) zona pellucida glycoprotein-C expressed in Escherichia coli and its corresponding synthetic peptide. Reprod Biomed Online 2001;2:33-9
78. Chen MS, Tung KS, Coonrod SA, et al. Role of the integrin-associated protein CD9 in binding between sperm ADAM2 and the egg integrin alpha6beta1: implications for murine fertilization. Proc Natl Acad Sci USA 1999;96:11830-5
79. Le Naour F, Rubinstein E, Jasmin C, et al. Severely reduced female fertility in CD9 deficient mice. Science 2000;287:319-21
80. Bianchi E, Doe B, Goulding D, Wright GJ. Juno is the egg Izumo receptor and is essential for mammalian fertilization. Nature 2014;508:483-7
81. Inoue N, Ikawa M, Isotani A, Okabe M. The immunoglobulin superfamily protein Izumo is required for sperm to fuse with eggs. Nature 2005;434:234-8
82. Pires ES, Hlavin C, Macnamara E, et al. SAS1B protein [ovastacin] shows temporal and spatial restriction to oocytes in several eutherian orders and initiates translation at the primary to secondary follicle transition. Dev Dyn 2013;242:1405-26
83. Stevens VC, Powell JE, Lee AC, et al. Antifertility effects of immunization of female baboons with C-terminal peptides of the beta-subunit of human chorionic gonadotropin. Fertil Steril 1981;36:98-105
84. Jones WR, Bradley J, Judd SJ, et al. Phase I clinical trial of a World Health Organisation birth control vaccine. Lancet 1988;1:1295-8
85. Talwar GP, Sharma NC, Dubey SK, et al. Isoimmunization against human chorionic gonadotropin with conjugates of processed beta-subunit of the hormone and tetanus toxoid. Proc Natl Acad Sci USA 1976;73:218-22
86. Nash H, Johansson ED, Talwar GP, et al. Observations on the antigenicity and clinical effects of a candidate antipregnancy vaccine: beta-subunit of human chorionic gonadotropin linked to tetanus toxoid. Fertil Steril 1980;34:328-35
87. Talwar GP, Singh O, Pal R, et al. A vaccine that prevents pregnancy in women. Proc Natl Acad Sci USA 1994;91:8532-6
88. Singh M, Das SK, Suri S, et al. Regain of fertility and normality of progeny born during below protective threshold antibody titres in women immunized with the HSD-hCG vaccine. Am J Reprod Immunol 1998;39:395-8
89. Leitner WW, Ying H, Restilo NP. DNA and RNA-based vaccines: principle, progress and prospects. Vaccine 1999;18:765-77
90. Wang XL, Zhao XR, Yu M, et al. Gene conjugation of molecular adjuvant C3d3 to hCG beta increased the antihCG beta Th-2 and humoral immune response in DNA immunization. J Gene Med 2006;8:498-505
91. Purswani S, Talwar GP. Development of a highly immunogenic recombinant candidate vaccine against human chorionic gonadotropin. Vaccine 2011;29:2341-8